392 material Form 8-K filings that 341 companies we cover made with the SEC in July 2024, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Centerspace reported second-quarter 2024 results and raised the midpoint of its 2024 Core FFO per diluted share outlook, narrowing the range to $4.78 to $4.92 from $4.74 to $4.92. Q2 net loss was $0.19 per diluted share, compared with a $0.23 loss a year earlier, while Core FFO per diluted share was $1.27 versus $1.28 in the prior-year quarter.
Updated 2024 Core FFO per diluted share outlook: $4.78 to $4.92, up from $4.74 to $4.92; net income per diluted share outlook raised to $(1.21) to $(1.01) from $(1.34) to $(1.10)
Q2 2024 net loss of $0.19 per diluted share vs. $0.23 loss in Q2 2023; Q2 Core FFO of $1.27 per diluted share vs. $1.28
Six-month Core FFO per diluted share rose 5.5% to $2.49; same-store NOI rose 2.4% in Q2 2024 year over year
Unsecured credit facility maturity extended to July 2028 on July 26, 2024; borrowing capacity stayed at $250.0 million
CNO Financial Group reported second-quarter 2024 net income of $116.3 million, or $1.06 per diluted share, up from $73.7 million, or $0.64 per diluted share, a year earlier. Net operating income rose to $114.6 million, or $1.05 per diluted share, and the company said it is raising full-year guidance on earnings and cash flow. The company returned $77.2 million to shareholders in the quarter through buybacks and dividends.
Net income of $116.3 million, or $1.06 per diluted share, in 2Q24 versus $73.7 million, or $0.64, in 2Q23
Net operating income of $114.6 million, or $1.05 per diluted share, in 2Q24 versus $62.3 million, or $0.54, in 2Q23
Full-year guidance raised on earnings and cash flow
Repurchased $60.0 million of common stock in 2Q24; 106.5 million shares outstanding at June 30, 2024
SBA Communications reported second-quarter 2024 total revenues of $660.5 million, down 2.7%, and net income of $159.5 million, or $1.51 per diluted share, down from $1.87 a year earlier. The company also lowered its full-year 2024 revenue and Adjusted EBITDA outlook, which weighs on shareholders, while declaring a $0.98 quarterly dividend.
Q2 2024 total revenues were $660.5 million, down from $678.5 million; net income was $159.5 million, or $1.51 per diluted share, versus $202.0 million, or $1.87, in Q2 2023
Net income included a $66.2 million after-tax loss on currency remeasurement of intercompany loans
Full-year 2024 total revenue outlook is now $2,642.0 million to $2,672.0 million, a $20.0 million cut at the midpoint; Adjusted EBITDA outlook is $1,876.0 million to $1,896.0 million, down $13.0 million at the midpoint
Quarterly dividend of $0.98 per share is payable September 18, 2024 to holders of record on August 22, 2024
Corcept Therapeutics reported second-quarter 2024 revenue of $163.8 million, up 39% from a year earlier, and raised its full-year 2024 revenue guidance to $640 million to $670 million from $620 million to $650 million. Diluted earnings per share were $0.32, compared with $0.25 in the second quarter of 2023, though operating expenses rose to $128.2 million from $88.1 million.
Q2 2024 revenue of $163.8 million, versus $117.7 million in Q2 2023
Diluted EPS of $0.32 versus $0.25; net income of $35.5 million versus $27.5 million
2024 revenue guidance raised to $640 million to $670 million from $620 million to $650 million
Cash and investments of $492.5 million at June 30, 2024, up from $451.0 million at March 31, 2024
Revvity reported second-quarter 2024 revenue of $692 million, down from $709 million a year earlier, while GAAP EPS rose to $0.45 from $0.28 and adjusted EPS from continuing operations was $1.22 versus $1.21. The company raised its full-year 2024 adjusted EPS guidance to $4.70-$4.80 and set revenue guidance at $2.77-$2.79 billion, citing currency changes and assumed 2% organic revenue growth. Shareholders see higher profit measures alongside a lower top line, with Life Sciences revenue down 7%.
Q2 2024 revenue was $692 million versus $709 million a year earlier; reported revenue fell 2% and organic revenue fell 1%.
GAAP EPS was $0.45 versus $0.28; adjusted EPS from continuing operations was $1.22 versus $1.21.
Full-year 2024 adjusted EPS guidance raised to $4.70-$4.80; revenue guidance updated to $2.77-$2.79 billion.
Life Sciences revenue fell 7% to $314 million; Diagnostics revenue rose 1% to $378 million.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.